Azeria Therapeutics is the world’s first pioneer factor drug discovery company developing breakthrough treatments for hormone resistant breast and prostate cancer patients where there are significant areas of unmet clinical need. Founded in 2017 by the leading expert in pioneer factors in cancer, Dr Jason Carroll, Azeria is using its proprietary drug screening platform to develop a pipeline of small molecules designed to identify selective pioneer factor inhibitors.

Contact Information

CRUK Cambridge Institute,, Robinson Way
Cambridge, MA
United States


Total FundingEmployeesLast Funding DateStatus

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2018-09-04$5,143,133Series ASixth Element Capital